BRAF and Miyoshi myopathy: Here, we evaluated the anti-tumor effects of barasertib-HQPA in MM cell models carrying BRAF(V600E) or BRAF(V600K) mutations and wild type BRAF in order to evaluate the efficacy of barasertib in cells responding to anti-BRAF vemurafenib and do not, respectively.